Indivior PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 06/04/2023
Indivior PLC Stock Forecast and Price Target
The average target price set lately by experts for Indivior PLC to reach by the end of the year is £4.74, which would imply a potential downside of approximately -97.14 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of £5.09 and a low estimate of £3.93. Even if you are not interested in INDV stock, you should still be aware of its competitors.
-97.14% Downside
Indivior PLC Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Price has decreased from £2.13 to £1.67 – a 21.74% drop! The next year looks promising for Indivior PLC, with analysts predicting Fair Value of £2.09 – an increase of 25.46%. Over the next nine years, experts anticipate that Indivior PLC's Fair Value will grow at a rate of 26.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$442.33 | Buy/Sell | $333.19 | -9.57% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$38.36 | Buy/Sell | $47.96 | 37.25% |
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.75k | Buy/Sell | £153.20 | -98.67% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr3.00k | Buy/Sell | kr2.84k | -8.24% |
| ARGX Stock Forecast | argenx | Buy |
4
|
358.10€ | Buy/Sell | 0.00€ | -0.31% |
Indivior PLC Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Revenue has grown, increasing from £785.00M to £791.00M – a growth of 0.76%. The next year, 0 experts forecast that Indivior PLC's Revenue will decrease by 5.02%, reaching £751.27M. In 2030, professionals predict that Indivior PLC's Revenue will decrease by 5.03%, reaching £751.19M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Hold |
12
|
$7.23 | Buy/Sell | $12.04 | 38.31% |
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
38.68€ | Buy/Sell | 49.03€ | 13.75% |
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
53.46€ | Buy/Sell | 34.70€ | -25.18% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ITCI Stock Forecast | Intra-Cellular Therapies | Outperform |
10
|
$61.32 | Buy/Sell | $68.92 | 14.16% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£1.80k | Buy/Sell | £29.33 | -98.47% |
| ALKS Stock Forecast | Alkermes | Hold |
10
|
$27.11 | Buy/Sell | $0.00 | 18.04% |
Indivior PLC Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Free Cash Flow has grown by 142.36%, rising from £144.00M to £349.00M. According to 0 prominent analysts, Indivior PLC's Free Cash Flow will fall by 47.54% in the next year, reaching £183.09M. By 2030, professionals believe that Indivior PLC's Free Cash Flow will decrease by 35.42%, reaching £225.38M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LUN Stock Forecast | H. Lundbeck A/S | Outperform |
18
|
kr23.88 | Buy/Sell | kr224.81 | 716.58% |
| ALK B Stock Forecast | ALK-Abelló A/S | Hold |
13
|
kr96.05 | Buy/Sell | kr3.35k | 84.80% |
| EVT Stock Forecast | Evotec | Outperform |
14
|
21.71€ | Buy/Sell | 37.33€ | 52.00% |
Indivior PLC Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Net Income has grown from £134.00M to £205.00M – a 52.99% increase. For the next year, 0 analysts project Indivior PLC's Net Income to drop by 51.29%, reaching £99.86M. By 2030, professionals believe that Indivior PLC's Net Income will decrease by 36.85%, reaching £129.46M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALM Stock Forecast | Almirall | Outperform |
16
|
8.56€ | Buy/Sell | 14.28€ | 63.55% |
| CLIN Stock Forecast | Clinigen Group | Outperform |
18
|
£9.25 | Buy/Sell | £7.78 | 75.89% |
| FAE Stock Forecast | Faes Farma | Hold |
18
|
3.36€ | Buy/Sell | 4.20€ | 25.00% |
Indivior PLC EBITDA Forecast for 2023 - 2025 - 2030
Indivior PLC's EBITDA has decreased In the last two years, from £214.00M to £198.00M – a 7.48% drop. For next year, analysts predict EBITDA of £207.17M, which would mean an increase of 4.63%. Over the next nine years, experts predict that Indivior PLC's EBITDA will grow at a rate of 3.34%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VEC Stock Forecast | Vectura Group | Hold |
14
|
£165.00 | Buy/Sell | £1.41 | -98.88% |
| PHM Stock Forecast | Pharma Mar | Outperform |
13
|
33.64€ | Buy/Sell | 0.00€ | 144.35% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF56.10 | Buy/Sell | CHF0.00 | 65.54% |
Indivior PLC EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's EBIT has seen a drop from £202.00M to £186.00M – a 7.92% decrease. In the next year, analysts believe that EBIT will reach £200.99M – an increase of 8.06%. For the next nine years, the forecast is for EBIT to grow by 6.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr117.00 | Buy/Sell | kr241.83 | 70.94% |
| MOR Stock Forecast | MorphoSys | Outperform |
6
|
24.45€ | Buy/Sell | 40.70€ | 41.10% |
| VNDA Stock Forecast | Vanda Pharmaceuticals | Hold |
0
|
$5.90 | Buy/Sell | $24.00 | 69.49% |
Indivior PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's EPS has decreased from £0.23 to £0.18 – a 21.74% drop! The next year looks promising for Indivior PLC, with analysts predicting EPS of £0.23 – an increase of 25.46%. Over the next nine years, experts anticipate that Indivior PLC's EPS will grow at a rate of 26.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NasdaqGS:BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | Buy/Sell | $10.00 | 78.89% |
| BSLN Stock Forecast | Basilea Pharmaceutica | Buy |
6
|
CHF42.26 | Buy/Sell | CHF87.60 | 72.74% |
| AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$2.55 | Buy/Sell | $0.00 | 174.51% |
.jpg)